AngioDynamics (STU:UG2) Stock Based Compensation: €12.0 Mil (TTM As of May. 2026)

Author: Vera Yuan Vera Yuan
Vera Yuan
Vera Yuan
Director of Data and Quant Analytics at GuruFocus
Focused on building reliable datasets, financial models, and research tools for value-minded investors. Committed to turning complex data into practical guidance for value-investing and long-term wealth.
Reviewed by: Charlie Tian Charlie Tian
Charlie Tian
Charlie Tian
Founder & CEO of GuruFocus
Dr. Charlie Tian is the founder and CEO of GuruFocus.com, a leading global investment research platform established in 2004. With a Ph.D. in physics, Dr. Tian transitioned from science to finance, applying a data-driven, disciplined approach to value investing.

STU:UG2 AngioDynamics Inc STU:UG2
66 GF Score
Price €11.80
GF Value €8.32
Valuation Significantly Overvalued
! 6 Warning Signs
View Full Analysis

What is AngioDynamics Stock Based Compensation?

AngioDynamics STU:UG2 -3.28% 66 Stock Based Compensation is €12.0 Mil as of May. 2026. GuruFocus rates STU:UG2 with a GF Score™ of 66/100 and a GF Value™ of €8.32 (Significantly Overvalued). The stock has 6 warning signs investors should review.

AngioDynamics's Stock Based Compensation for the three months ended in May. 2026 was €3.4 Mil. Its Stock Based Compensation for the trailing twelve months (TTM) ended in May. 2026 was €12.0 Mil.

AngioDynamics Stock Based Compensation Related Terms

AngioDynamics Stock Based Compensation Historical Data

* Premium members only.

The historical data trend for AngioDynamics's Stock Based Compensation can be seen below:

* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD.
* For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.

AngioDynamics Stock Based Compensation Chart

AngioDynamics Annual Data
Trend May17 May18 May19 May20 May21 May22 May23 May24 May25 May26
Stock Based Compensation
Get a 7-Day Free Trial Premium Member Only Premium Member Only 10.12 10.27 9.74 8.67 11.95

AngioDynamics Quarterly Data
Aug21 Nov21 Feb22 May22 Aug22 Nov22 Feb23 May23 Aug23 Nov23 Feb24 May24 Aug24 Nov24 Feb25 May25 Aug25 Nov25 Feb26 May26
Stock Based Compensation Get a 7-Day Free Trial Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only 1.46 3.84 2.50 2.27 3.35
STU:UG2
66GF Score
AngioDynamics Inc STU:UG2
Stock Based Compensation is just one metric. See GF Score™, valuation, warning signs, and more.
View Full Analysis

AngioDynamics Stock Based Compensation Calculation

Stock Based Compensation is a way corporations use stock options to reward employees. It provides executives and employees the opportunity to share in the growth of the company and, if structured properly, can align their interests with the interests of the company's shareholders and investors, without burning the company's cash on hand.

Stock Based Compensation for the trailing twelve months (TTM) ended in May. 2026 adds up the quarterly data reported by the company within the most recent 12 months, which was €12.0 Mil.

What does a Stock Based Compensation of €12.0 Mil mean?
AngioDynamics (STU:UG2) has a Stock Based Compensation of €12.0 Mil as of May. 2026. Stock based compensation is the amount of company stock issued as employee benefits. View historical data for AngioDynamics and its competitors.
Is AngioDynamics' Stock Based Compensation too high?
AngioDynamics' current Stock Based Compensation is €12.0 Mil. Overall, AngioDynamics has a GF Score™ of 66/100 and is considered Significantly Overvalued, reflecting its overall financial health beyond just this single metric.
How does AngioDynamics' Stock Based Compensation compare to NNNN and OSUR?
AngioDynamics' Stock Based Compensation of €12.0 Mil can be compared against companies in the Medical Devices & Instruments industry. See the competitive comparison table and distribution chart on this page for a detailed peer-by-peer breakdown.
What is a good Stock Based Compensation for a Medical Devices & Instruments company?
A good Stock Based Compensation depends on the Medical Devices & Instruments industry context. However, Stock Based Compensation should not be evaluated in isolation — investors should consider it alongside profitability, growth, and financial strength metrics. Use the industry distribution chart on this page to see where any company falls relative to its peers.
What does a high Stock Based Compensation mean?
A high Stock Based Compensation can signal that a stock is expensive relative to its fundamentals. Stock based compensation is the amount of company stock issued as employee benefits. View historical data for AngioDynamics and its competitors. AngioDynamics's current Stock Based Compensation is €12.0 Mil. However, context matters — high-growth companies often justify higher valuations. Always evaluate alongside other metrics like GF Score™ and GF Value™.
Is AngioDynamics stock overvalued right now?
Based on GuruFocus' analysis, AngioDynamics (STU:UG2) is currently considered Significantly Overvalued. The stock's GF Value™ is €8.32, compared to a current price of €11.80 — trading 41.8% above its estimated fair value. The current Stock Based Compensation is €12.0 Mil. AngioDynamics' overall GF Score™ is 66/100 with 6 warning signs to review. Investors should evaluate multiple metrics — including profitability, growth, and financial strength — before making a decision.
How is Stock Based Compensation calculated?
Stock Based Compensation is calculated from a company's financial statements. For AngioDynamics (STU:UG2), the current Stock Based Compensation is €12.0 Mil as of May. 2026. GuruFocus calculates this using data sourced from SEC filings and annual reports. See the calculation section and 30-year financial data on this page for the full breakdown.

Is AngioDynamics (STU:UG2) Overvalued in 2026?

Based on GuruFocus' analysis, AngioDynamics stock appears to be overvalued. The current stock price of €11.80 is trading 41.8% above its estimated GF Value™ of €8.32. GuruFocus considers AngioDynamics to be Significantly Overvalued.

Key valuation signals for STU:UG2:

  • Stock Based Compensation: €12.0 Mil
  • GF Value™: €8.32 vs. price of €11.80 (41.8% above fair value)
  • GF Score™: 66/100 with 6 warning signs

No single metric tells the full story. See the STU:UG2 stock analysis page for a complete view including 30-year financials, guru trades, and insider activity.

AngioDynamics Business Description

Other Exchanges ANGO:USA
Address 14 Plaza Drive, Latham, NY, USA, 12110
AngioDynamics Inc designs manufactures, and sells medical, surgical, and diagnostic devices used by professional healthcare providers for the treatment of peripheral vascular disease and for use in oncology and surgical settings. Geographically, the company derives a majority of its revenue from the United States from sale of Med Tech and Med Device.
66GF Score

Get the complete analysis for STU:UG2

Stock Based Compensation is just one metric. See GF Value™, 30-year financials, guru trades, warning signs, and more.

€11.80
Price
€8.32
GF Value